Dimensional Fund Advisors LP Acquires 8,521 Shares of Intuitive Surgical, Inc. $ISRG

Key Points

• Dimensional Fund Advisors LP increased its stake in Intuitive Surgical, Inc. by 1.5%, owning approximately $284.75 million worth of shares as of the latest SEC disclosure.
• Institutional investors own about 83.64% of Intuitive Surgical's stock, indicating strong institutional interest in the company.
• Analysts have varying ratings for Intuitive Surgical, with a consensus rating of "Moderate Buy" and a target price around $595.95.

Dimensional Fund Advisors LP lifted its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 1.5% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 574,954 shares of the medical equipment provider's stock after buying an additional 8,521 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.16% of Intuitive Surgical worth $284,746,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of ISRG. Chilton Capital Management LLC grew its holdings in Intuitive Surgical by 614.3% in the first quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 43 shares during the period. Parvin Asset Management LLC purchased a new stake in Intuitive Surgical in the fourth quarter valued at approximately $26,000. Global Financial Private Client LLC grew its holdings in Intuitive Surgical by 253.3% in the first quarter. Global Financial Private Client LLC now owns 53 shares of the medical equipment provider's stock valued at $26,000 after purchasing an additional 38 shares during the period. Elite Financial Inc. purchased a new stake in Intuitive Surgical in the first quarter valued at approximately $26,000. Finally, LFA Lugano Financial Advisors SA purchased a new stake in Intuitive Surgical in the first quarter valued at approximately $30,000. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Intuitive Surgical

In related news, SVP Mark Brosius sold 216 shares of the stock in a transaction dated Friday, June 6th. The shares were sold at an average price of $563.11, for a total value of $121,631.76. Following the completion of the transaction, the senior vice president owned 907 shares in the company, valued at $510,740.77. This represents a 19.23% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Myriam Curet sold 4,500 shares of the stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $492.48, for a total transaction of $2,216,160.00. Following the completion of the transaction, the executive vice president owned 353 shares of the company's stock, valued at $173,845.44. This represents a 92.73% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 15,839 shares of company stock worth $7,896,972. Insiders own 0.70% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on ISRG. BTIG Research boosted their target price on shares of Intuitive Surgical from $566.00 to $571.00 and gave the company a "buy" rating in a report on Wednesday, July 23rd. UBS Group boosted their target price on shares of Intuitive Surgical from $547.00 to $585.00 and gave the company a "neutral" rating in a report on Wednesday, July 23rd. Robert W. Baird decreased their price objective on shares of Intuitive Surgical from $600.00 to $575.00 and set an "outperform" rating for the company in a research note on Wednesday, April 23rd. Citigroup reiterated a "buy" rating and set a $650.00 price objective (up from $590.00) on shares of Intuitive Surgical in a research note on Thursday, May 22nd. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of Intuitive Surgical from a "hold" rating to a "sell" rating and decreased their price objective for the stock from $515.00 to $440.00 in a research note on Monday, June 9th. Thirteen equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $595.95.

Intuitive Surgical Stock Up 0.3%

Shares of NASDAQ ISRG traded up $1.25 during trading on Wednesday, reaching $480.45. 1,409,146 shares of the stock were exchanged, compared to its average volume of 1,989,028. The business's 50-day moving average price is $506.84 and its 200 day moving average price is $523.82. Intuitive Surgical, Inc. has a twelve month low of $425.00 and a twelve month high of $616.00. The company has a market capitalization of $172.23 billion, a price-to-earnings ratio of 67.01, a price-to-earnings-growth ratio of 5.04 and a beta of 1.59.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its quarterly earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.93 by $0.26. The firm had revenue of $2.44 billion for the quarter, compared to analysts' expectations of $2.35 billion. Intuitive Surgical had a net margin of 28.51% and a return on equity of 14.56%. The firm's quarterly revenue was up 21.4% on a year-over-year basis. During the same period in the prior year, the company posted $1.78 earnings per share. As a group, sell-side analysts expect that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.